Valentina Tarau-Sas

Mrs. Valentina Tarau-Sas

Pediatrics, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Cluj, Romania
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VTValentina Tarau-Sas
Valentina Tarau-Sas
VMVlad Moisoiu
Vlad Moisoiu
PTPatric Teodorescu
Patric Teodorescu
STSebastian Tranca
Sebastian Tranca
LPLaura-Ancuta Pop
Laura-Ancuta Pop
RTRomanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation
Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation
During recent decades, understanding of the molecular mechanisms of acute lymphoblastic leukemia (ALL) has improved considerably, resulting in better risk stratification of patients and increased survival rates. Age, white blood cell count (WBC), and specific genetic abnormalities are the most important factors that define risk groups for ALL. State-of-the-art diagnosis of ALL requires cytological and cytogenetical analyses, as well as flow cytometry and high-throughput sequencing assays. An important aspect in the diagnostic characterization of patients with ALL is the identification of the Philadelphia (Ph) chromosome, which warrants the addition of tyrosine kinase inhibitors (TKI) to the chemotherapy backbone. Data that support the benefit of hematopoietic stem cell transplantation (HSCT) in high risk patient subsets or in late relapse patients are still questioned and have yet to be determined conclusive. This article presents the newly published data in ALL workup and treatment, putting it into perspective for the attending physician in hematology and oncology.

19 May 2019 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
VTValentina Tarau-Sas
Valentina Tarau-Sas
CBCristina Blag
Cristina Blag
GZGabriela Zaharie
Gabriela Zaharie
EPEmil Puscas
Emil Puscas
CLCosmin Lisencu
Cosmin Lisencu
CTCiprian Tomuleasa
Ciprian Tomuleasa
Childhood leukemia is mostly a ‘‘developmental accident’’ during fetal hematopoiesis and may require multiple prenatal and postnatal ‘‘hits’’. The World Health Organization defines transient leukemia of Down syndrome as increased peripheral blood blasts cells in neonates with Down syndrome and classifies this type of leukemia as a separate entity. Although it was shown that Down syndrome predisposes children to myeloid leukemia, neither the nature of the predisposition nor the associated genetic lesions have been defined. Acute myeloid leukemia of Down syndrome is a unique disease characterized by a long pre-leukemic, myelodysplastic phase, unusual chromosomal findings and a high cure rate. In the present manuscript, we present a comprehensive review of the literature about clinical and biological findings of transient leukemia of Down syndrome and link them with the genetic discoveries in the field. We address the manuscript to the pediatric generalist and especially to the next generation of pediatric hematologists.

30 October 2025 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
CPCristina Pantelemon
Cristina Pantelemon
LCLacramioara Eliza Chiperi
Lacramioara Eliza Chiperi
BIBianca Iftimie
Bianca Iftimie
Livia Livinț-PopaLivia Livinț-Popa
Livia Livinț-Popa
VTValentina Tarau-Sas
Valentina Tarau-Sas
DMDafin Fior Muresanu
Dafin Fior Muresanu
Background/Objectives: Sleep disturbances are among the most prevalent and persistent comorbidities in children and adolescents with autism spectrum disorder (ASD), affecting up to 83% of this population. These disturbances not only impact the quality of life but are increasingly recognized as significant contributors to behavioral dysregulation. Methods: This systematic review synthesizes evidence from 26 studies published between 2010 and 2024, examining the association between sleep problems and behavioral outcomes in individuals with ASD aged 2 to 18 years. Results: The findings reveal consistent associations between sleep-onset insomnia, night walking, bedtime resistance, and various behavioral difficulties, including aggression, hyperactivity, and emotional dysregulation. Internalizing symptoms and exacerbation of core ASD features were also linked to chronic sleep problems. Studies employing objective sleep measures, such as actigraphy and polysomnography, further supported these associations by identifying disruptions in sleep architecture correlated with behavioral severity. While most included studies were of moderate to high methodological quality, the limited number of randomized controlled trials and heterogeneity of sleep and behavior assessment tools highlight the need for standardization. Conclusions: Overall, the review emphasizes the importance of routine sleep evaluation in ASD clinical care and supports targeted sleep interventions as a potential strategy to reduce behavioral problems and improve developmental outcomes.

12 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VTValentina Tarau-Sas
Valentina Tarau-Sas
Paraschiva CHERECHES-PANTAParaschiva CHERECHES-PANTA
Paraschiva CHERECHES-PANTA
DBDiana Alexandra Borcau
Diana Alexandra Borcau
CSCristina-Nicoleta Schnell
Cristina-Nicoleta Schnell
EIEdita-Gabriela Ichim
Edita-Gabriela Ichim
SMSorin Claudiu Man
Sorin Claudiu Man
Electronic nose (e-nose) is a new technology applied for the identification of volatile organic compounds (VOC) in breath air. Measuring VOC in exhaled breath can adequately identify airway inflammation, especially in asthma. Its noninvasive character makes e-nose an attractive technology applicable in pediatrics. We hypothesized that an electronic nose could discriminate the breath prints of patients with asthma from controls. A cross-sectional study was conducted and included 35 pediatric patients. Eleven cases and seven controls formed the two training models (models A and B). Another nine cases and eight controls formed the external validation group. Exhaled breath samples were analyzed using Cyranose 320, Smith Detections, Pasadena, CA, USA. The discriminative ability of breath prints was investigated by principal component analysis (PCA) and canonical discriminative analysis (CDA). Cross-validation accuracy (CVA) was calculated. For the external validation step, accuracy, sensitivity and specificity were calculated. Duplicate sampling of exhaled breath was obtained for ten patients. E-nose was able to discriminate between the controls and asthmatic patient group with a CVA of 63.63% and an M-distance of 3.13 for model A and a CVA of 90% and an M-distance of 5.55 for model B in the internal validation step. In the second step of external validation, accuracy, sensitivity and specificity were 64%, 77% and 50%, respectively, for model A, and 58%, 66% and 50%, respectively, for model B. Between paired breath sample fingerprints, there were no significant differences. An electronic nose can discriminate pediatric patients with asthma from controls, but the accuracy obtained in the external validation was lower than the CVA obtained in the internal validation step.

16 October 2025 in Children
Verified
Journal Article
Open access
PDF file
Paraschiva CHERECHES-PANTAParaschiva CHERECHES-PANTA
Paraschiva CHERECHES-PANTA
IMIoana Marica
Ioana Marica
VTValentina Tarau-Sas
Valentina Tarau-Sas
ABAlina Petronela Bouari-Coblișan
Alina Petronela Bouari-Coblișan
SMSorin Claudiu Man
Sorin Claudiu Man
Background: Asthma is the most common chronic disease during childhood. Spirometry is recommended as a reliable lung function test. Several studies have demonstrated the lack of use of spirometry for both diagnostic confirmation and monitoring. Using subjective symptom control tests alone may underestimate the risk for future asthma attacks. Methods/Objectives: We conducted a retrospective, observational study in a single pediatric centre in Romania. The main objectives of the study were to analyse the quality of spirometry in children and to emphasise the importance of performing accurate spirometry for asthma monitoring. The secondary objective was to evaluate if forced expiratory volume in the first second (FEV1) and mid-maximum expiratory flow (MMEF) values are predictive markers for future exacerbations in children with asthma. Results: The study group included 416 patients between 5 and 18 years who performed at least one spirometry. The success rate for spirometry in our study was 66.3%. In a subsequent study group of 88 patients we monitored spirometry initially and after 12 months. We found a statistically significant difference between FEV1 and MMEF in the controlled, partially controlled and uncontrolled groups (p = 0.0102 and p = 0.0001). Our study showed no association between FEV1 and risk for exacerbations (Rs = −0.156, p = 0.146) and an acceptably negative (Rs = −0.30) and statistically significant (p = 0.040) correlation between initial MMEF values and the number of exacerbations. Conclusions: Low initial MMEF values correlate with the number of exacerbations in a 12-month follow-up period. This suggests that evaluating MMEF alongside FEV1 in children with asthma could contribute to better identification of the risk of exacerbation.

3 October 2020 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
VTValentina Tarau-Sas
Valentina Tarau-Sas
Sergiu PascaSergiu Pasca
Sergiu Pasca
AJAncuta Jurj
Ancuta Jurj
LPLaura-Ancuta Pop
Laura-Ancuta Pop
HMHideki Muramatsu
Hideki Muramatsu
CTCiprian Tomuleasa
Ciprian Tomuleasa
Down syndrome associated disorders are caused by a complex genetic context where trisomy 21 is a central component in relation to other changes involving epigenetic regulators and signaling molecules. This unique genetic context is responsible for the predisposition of people with Down syndrome to acute leukemia. Although, the research in this field has discovered some important pathogenic keys, the exact mechanism of this predisposition is not known. In this study we applied functional enrichment analysis to evaluate the interactions between genes localized on chromosome 21, genes already identify as having a key role in acute leukemia of Down syndrome, miRNAs and signaling pathways implicated in cancer and cell development and found that miR-155 has a high impact in genes present on chromosome 21. Forward, we performed next generation sequencing on DNA samples from a cohort of patients diagnosed with acute leukemia of Down syndrome and in vitro functional assay using a CMK-86 cell line, transfected with either mimic or inhibitor of the microRNA-155-5p. Our results show that the epigenetic alteration of the TNF superfamily receptors in Down syndrome, which can be correlated to microRNA-155-5p aberrant activity, may play an important role in cell signaling and thus be linked to acute myeloid leukemia. Some genes, already shown to be mutated in AML-DS, are potential targets for miR-155. Our results show that the epigenetic alteration of the TNF superfamily receptors in Down syndrome may play an important role in cell signaling and thus be linked to acute myeloid leukemia.